Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Cell Res
; 32(4): 404-406, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-35087243
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
En
Journal:
Cell Res
Year:
2022
Document type:
Article
Affiliation country:
China